Amgen Inc. (NASDAQ:AMGN) Shares Sold by RWA Wealth Partners LLC

RWA Wealth Partners LLC reduced its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 2.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 32,339 shares of the medical research company’s stock after selling 838 shares during the quarter. RWA Wealth Partners LLC’s holdings in Amgen were worth $8,429,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Quantbot Technologies LP purchased a new stake in shares of Amgen in the 3rd quarter valued at about $150,000. Public Sector Pension Investment Board lifted its stake in Amgen by 14.0% in the third quarter. Public Sector Pension Investment Board now owns 23,547 shares of the medical research company’s stock valued at $7,587,000 after buying an additional 2,900 shares during the last quarter. Caisse DE Depot ET Placement DU Quebec boosted its holdings in shares of Amgen by 64.7% in the third quarter. Caisse DE Depot ET Placement DU Quebec now owns 293,333 shares of the medical research company’s stock valued at $94,515,000 after acquiring an additional 115,210 shares during the period. Ironwood Investment Counsel LLC grew its position in shares of Amgen by 3.7% during the third quarter. Ironwood Investment Counsel LLC now owns 4,784 shares of the medical research company’s stock worth $1,542,000 after acquiring an additional 170 shares during the last quarter. Finally, Kolinsky Wealth Management LLC increased its holdings in shares of Amgen by 4.4% in the 3rd quarter. Kolinsky Wealth Management LLC now owns 2,241 shares of the medical research company’s stock valued at $722,000 after acquiring an additional 95 shares during the period. 76.50% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

AMGN has been the topic of several research reports. Citigroup reissued a “neutral” rating on shares of Amgen in a research report on Wednesday, February 5th. Royal Bank of Canada restated an “outperform” rating and issued a $324.00 price target on shares of Amgen in a research report on Friday, January 24th. Piper Sandler increased their price objective on Amgen from $310.00 to $329.00 and gave the stock an “overweight” rating in a research report on Monday, February 10th. StockNews.com raised Amgen from a “buy” rating to a “strong-buy” rating in a report on Saturday. Finally, Bank of America increased their price target on Amgen from $275.00 to $294.00 and gave the stock an “underperform” rating in a report on Wednesday, March 5th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating, eleven have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, Amgen presently has a consensus rating of “Moderate Buy” and an average price target of $314.04.

Insider Activity at Amgen

In related news, EVP Jonathan P. Graham sold 25,045 shares of the stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $293.12, for a total transaction of $7,341,190.40. Following the transaction, the executive vice president now directly owns 28,987 shares in the company, valued at approximately $8,496,669.44. This represents a 46.35 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP David M. Reese sold 8,711 shares of Amgen stock in a transaction dated Wednesday, February 19th. The shares were sold at an average price of $293.22, for a total value of $2,554,239.42. Following the completion of the sale, the executive vice president now owns 62,147 shares of the company’s stock, valued at $18,222,743.34. This trade represents a 12.29 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 69,341 shares of company stock valued at $20,644,335. Company insiders own 0.69% of the company’s stock.

Amgen Trading Up 0.4 %

Shares of Amgen stock opened at $306.95 on Friday. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The company has a debt-to-equity ratio of 9.62, a current ratio of 1.26 and a quick ratio of 0.95. The business has a 50 day moving average price of $301.08 and a 200 day moving average price of $298.16. The company has a market capitalization of $164.90 billion, a P/E ratio of 40.66, a P/E/G ratio of 2.63 and a beta of 0.53.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Tuesday, February 4th. The medical research company reported $5.31 earnings per share for the quarter, topping analysts’ consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. Sell-side analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Friday, May 16th will be given a $2.38 dividend. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.10%. The ex-dividend date of this dividend is Friday, May 16th. Amgen’s dividend payout ratio is presently 126.09%.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.